



Bellevue Group results 2020

Presentation for investors, analysts and the media

Zurich, March 2, 2021

Disclaimer

This document was produced by and the opinions expressed are those of Bellevue Group AG («Bellevue») as of the date of writing and are subject to change. It has been prepared solely for information purposes and for the use of the recipient. It does not constitute an offer or an invitation by or on behalf of Bellevue to any person to buy or sell any security. Any reference to past performance is not necessarily a guide to the future. The information and analysis contained in this publication have been compiled or arrived at from sources believed to be reliable but Bellevue does not make any representation as to their accuracy or completeness and does not accept liability for any loss arising from the use hereof.

This document is not an offering prospectus pursuant to Art. 652a of the Swiss Federal Code of Obligation or a listing prospectus pursuant to the listing rules of the SWX Swiss Exchange.

This publication is not being issued in the United States of America and should not be distributed to United States Persons or publications with a general circulation in the United States. This document does not constitute an offer or invitation to subscribe for or purchase any securities. In addition, the securities of Bellevue Group AG have not been registered under the United States Securities Laws and may not be offered, sold or delivered within the United States or to U.S. Persons absent from registration under or an applicable exemption from the registration requirements of the United States Securities Laws.

Agenda

- 
- 1 ***A Summary of Fiscal 2020***
André Rüegg, Group CEO
 - 2 ***Results for Fiscal 2020***
Michael Hutter, Group CFO
 - 3 ***Business & Strategy Update***
André Rüegg, Group CEO
 - 4 ***Outlook & Summary***
 - 5 ***Questions & Answers***
 -  ***Appendix***
↓



1

A Summary of Fiscal 2020

André Rüegg, Group CEO

2020 a record year highlighted by healthcare



Consistent strategy execution

- Successful **sale of Bank am Bellevue**
- Transformation to a **pure specialized asset manager** concluded
- **Evolution** of time-tested business model and **innovation** across the product range continue



Strong operating performance

- **Record financial results** despite turbulent markets
- **Convincing absolute and relative investment performance** of Bellevue products
- **Attractive value** created for shareholders and clients



Simplified & stronger platform

- Simplified, robust and agile **organization and capital base**
- **Very resilient platform, primed for further growth**
- **Solid governance** with a focus on **ESG**

Key figures 2020

Positive development of performance criteria

Client assets

CHF **12.0** bn
(31.12.19: CHF 10.6 bn)

Net new money

CHF **377** mn
(prev. period: CHF 422 mn)

Total operating income

CHF **109.9** mn
(prev. period: CHF 101.4 mn)

Operating profit (EBTDA) ¹⁾

CHF **46.3** mn
(prev. period: CHF 40.5 mn)

Profit after tax

CHF **22.3** mn
(prev. period: CHF 14.0 mn)

Cost Income ratio (CiR)

58%
(prev. period: 60%)

Return on equity ²⁾

21.7%
(prev. period: 12.2%)

Dividend yield ³⁾

4.9%
(prev. period: 5.2%)

- 1) Earnings of continuing business activities before taxes, depreciation and amortization
- 2) Based on group net profit and average shareholders' equity after deduction of the proposed dividend
- 3) Based on ordinary dividend of CHF 1.50 and share price on December 31, 2020

COVID-19: Bellevue Group demonstrates resiliency

Our healthcare expertise in a “sweet spot”



Resilient business model with attractive positioning

Organization - robust and agile

- Smooth operations ensured with split on-site staff
- Modern infrastructure demonstrated its value with on-site and remote arrangement

Healthcare expertise – solid and credible

- Clearly heightened international awareness of the healthcare sector
- Widely recognized as a specialized asset manager (numerous "COVID-19" updates)

Employees – motivated & entrepreneurial


- Very strong commitment at every level of the organization
- Working remotely, employees showed good self-management skills, assumed responsibility and were results-driven

Client service – intense interaction & “close despite distance”

- Targeted deployment of digital media and instruments enables intense and frequent interaction with clients and prospects
- High satisfaction rate and acquisition of new clients despite the lockdown




Convincing healthcare investment strategies (absolute performance 2020, in USD)



Client assets at all-time high – despite unprecedented market turmoil

Sustainable growth in assets under management, 2015 – 2020

CHF million




Assets under management top CHF 12.0 bn, setting another record high

- Assets under management show another significant increase of CHF 1.4 bn or 14%, fueled by market performance and new money inflows – despite the plunge in prices in March 2020 caused by the COVID-19 pandemic
- Long-term growth momentum is still intact – COVID-19 pandemic was an opportunity to further sharpen our expert profile in our core segment
- Time-tested investment expertise and product range deliver steady growth
- Attention in 2021 will continue to focus on direct equity investments and the launch of innovative products

Core “Healthcare” strategies attract more than CHF 1 bn for the first time

Growth of AuM in 2020

CHF million



Assets under management increase 14% thanks to new money inflows and performance-driven growth


- Net new money of CHF 377 mn represents exclusively organic growth
- Investment strategies in Healthcare, our core area of expertise, attract more than CHF 1 bn in net new money for the first time in the history of the company. These inflows are spread across the entire range of our healthcare investment solutions
- Differentiated alternative investment solutions (incl. the new “Private Markets” unit) show stability despite the market turbulence
- Asset outflows from traditional investment vehicles slowed versus the previous year – but bond and multi-asset strategies remained pressured by ruthless structural competition
- Termination of a large institutional mandate with a very low margin had a negligible impact on income

Further improvement in operating income with intact momentum

Growth of operating income, 2015 – 2020 (continuing operations)

Operating income

CHF million



Operating income climbs more than 8% to CHF 110 mn

- Core asset management business generates record operating income of CHF 110 mn despite dramatic slump in Q1 2020
- The 7.3% increase in recurring asset-based income does not yet reflect the strong H2 2020 growth in AuM, which will not feed through to income until H1 2021
- Slight y-o-y increase in non-recurring income, due to significantly lower performance fees of CHF 3.8 mn (prev. period: CHF 6.3 mn), but private equity generates solid income of CHF 2.5 mn (prev. period: CHF 1.0 mn)

Still focused on the business model of recurring income

- Recurring income share of total income, > 93%, remains at a very high level








2

Results for Fiscal 2020

Michael Hutter, Group CFO

Consolidated results


Total operating income




- Total operating income up 8.4%
- Management fees up 7.3% thanks to higher average asset base and new money with attractive margins
- Performance fees declined by about CHF 2.5 mn
- Other fee & commission income (net) mainly reflects transaction fees in the Group's private equity business. Income here rose by CHF 2.1 mn year-on-year
- Income from financial investments is totally dependent on the market. Investments in own products and other financial instruments generated a net positive result in 2020
- Other income (net) represents interest income, dividend income and other earnings

Consolidated results

Operating expenses and operating profit









- Increase in personnel expenses largely attributable to the greater number of employees, higher profit-based compensation and expenses related to a voluntary employee stock purchase plan
- Operating costs related to events and travel declined due to COVID-19
- Operating profit increased by more than 14%
- Significant improvement in cost/income ratio to 58%
- Clearly lower CIR thanks to significant increase in earnings and proportionately slower increase in cost base
- The operating profit-based CIR for 2020 confirms the positive downward-pointing long-term trend
- Steady efficiency gains possible thanks to scalability model



* Earnings of continuing business activities before taxes, depreciation and amortization

Consolidated results

Group net profit




- Increase in depreciation and value adjustments reflects the divestment of Bank am Bellevue and investment expenditures
- Lower AuM and operating results led to another negative value adjustment of CHF 9.6 mn at StarCapital
- Taxes increased as expected given the higher pretax profit
- The bottom line showed an 18% increase in profit from continuing operations to CHF 23.0 mn
- The net loss from discontinued operations (Bank am Bellevue) was sharply lower at CHF 0.7 mn
- Group net profit jumped 59% to CHF 22.3 mn

Capital structure and management

As of December 31, 2020 (consolidated)

CHF million




- Equity base remains strong despite special dividend payout in 2020 (CHF 37 mn) thanks to sustained earnings power
- Reduction in goodwill & intangibles (prev. period: CHF 64 mn), after extraordinary value adjustment and impairment at StarCapital
- Required level of regulatory minimum capital as a pure asset manager is lower, enabling a very attractive return on equity
- Reserves of CHF 73 mn create more even leeway for attractive payouts and expansion projects
- Simple and debt-free balance sheet

Attractive value creation for shareholders


Confidence in the business model is reflected in the dividend policy

General reserves

CHF million



Ordinary dividend over time



Dividend yield ¹⁾

6.4%	4.5%	5.6%	5.2%	4.9%
------	------	------	------	------

¹⁾ Based on ordinary dividend of CHF 1.50 and share price on December 31, 2020

Proposed total dividend of CHF 4.00 per share

- Significant 20% increase in ordinary dividend to CHF 1.50 per share, which reflects solid earnings power and management confidence
- Proceeds from the sale of Bank am Bellevue and a further drawdown of surplus equity permit payment of a special dividend of CHF 2.50 per share
- After this payout, there would no longer be any potential for further extraordinary payouts. After the proposed payouts, equity would amount to CHF 112 mn

Shareholder-friendly dividend policy confirmed

- Steadier earnings underpin an attractive dividend policy over the long term
- Regular dividend growth underscores confidence in the business model and the company's growth potential



3

Business & Strategy Update

André Rüegg, Group CEO

Bellevue Highlights 2020

Transformation to a pure asset manager completed – solid progress made

“Purpose”

Clear strategy & philosophy
as pure asset manager



Convincing investment
expertise, innovation &
accountability



Generate
outperformance
for our investors



Generate attractive
and steady returns
for shareholders

“Performance”

Strong performer &
consistent execution

- **Transformation process**
methodically implemented and now completed

- Growing and attractive offering
reflects strong **innovation power**

- Strong **absolute performance**
despite dramatic turbulence

- Competitive **relative performance**
versus relevant indexes and
competitors

- Strong **financial performance**

- Attractive **dividend policy**

- **Strong market performance**
reflects market trust

“Platform”

Resilient, agile and scalable
organization

- Much **less complexity, much more favorable risk profile** thanks to
exclusive focus on asset mngt

- simplified, robust and agile
organization with a **lean
management structure**

- High degree of **scalability** and
resilience provide considerable
growth potential and further
efficiency gains

- **Attractive profile as an employer**
enables steady expansion of **expert
and talent pool**

- **Reduced regulatory capital
requirements** and smaller capital
base enable **attractive ROE**

- Solid **governance** with a focus
on **ESG** – at operational and product
level

Steady value creation for shareholders over the long term

Comparison of key figures 2015 – 2020

	2015*		Δ		2020
<i>Client assets</i>	CHF 6.8 bn	+	77% (12.0% p.a.)	=	CHF 12.0 bn
<i>Total operating income</i>	CHF 80.0 mn	+	37% (6.6% p.a.)	=	CHF 109.9 mn
<i>Operating profit</i>	CHF 27.8 mn	+	67% (10.7% p.a.)	=	CHF 46.3 mn
<i>Scale effects & efficiency</i> <ul style="list-style-type: none"> • FTE • AuM/FTE • EBITDA/FTE • CIR 	87 CHF 78.2 mn CHF 320,000 68.2%		+ 13.8% + 55.0% + 46.3% - 10.2 pt.	=	99 CHF 121.2 mn CHF 468,000 58.0%

* Figures incl. Bank am Bellevue

Attractive product offering and solid investment performance

High level of quality and continuity clearly create value for Bellevue clients

Very competitive performance of investment strategies



- 72% of AuM in 1st or 2nd quartile in 2020
- 82% of AuM in 1st and 2nd quartile over 3 years
- 93% of AuM in 1st and 2nd quartile since inception
- 80% of AuM in 1st quartile since inception

*Value generation for investors («alpha»)**



- 79% of AuM beat benchmark in 2020
- 75% of AuM beat benchmark over 3 years
- 84% of AuM beat benchmark since inception

High continuity and stability in portfolio management



- 16 of 19 lead portfolio managers in charge since date of launch
- No portfolio manager changes in 2020
- Very low fluctuation rates for >10 years
- Steady recruitment of new investment professionals and young talents

* Outperformance after expenses, based on institutional share classes

Our forward and growth strategy

Growth = product quality + innovation + customer momentum

Strategic product directions


«Grow with the Products»

«Innovate»

«Renovate & clean up»



Strategic market and customer developments



AuM base 2020 = CHF 12.0 bn

Number of intermediary and institutional clients ~ 1'000

Product development and innovation are fueling growth

Strategic priorities and developments 2020

Strategic focal points

«Grow with the products»

«Innovate»

«Renovate & clean up»

New developments in 2020

- 3 flagship products > CHF 1 bn
- 2-3 other «blockbusters» could reach 1 bn mark
- 6 products with AuM between CHF 250 mn – 1 bn
- >75% of product range has reached critical mass

- Successful launch of «BB Pureos Bioventures»
- «Club Deals» for entrepreneurial investments in DACH arranged, enhanced
- «BB Entrepreneur Private» launched
- Implementation of «ESG integration» in all products
- Full pipeline of ideas for 2021/22

- Various products tweaked or augmented
- >10 products strategies closed or realigned

Effects & Benefits


- Simplified market and client access (platforms)
- Substantial scale effects/marginal profit
- Hardly no capacity limits

- Significant diversification steps (e.g. Private Markets)
- Making inroads into new client segments and markets
- Ongoing development of our “House of Ideas” profile
- Retention of future potential

- Ongoing adjustment to market environment and client needs
- Orderly retreat from easily replaceable strategies with high margin pressure

Client and growth momentum

Client network continues to grow despite the lockdowns



Strong growth in “core markets” across all segments

- Switzerland, Germany, UK (local presence in country)
- Strong growth in demanding client segment (big banks, private banks, institutions) thanks to product size and maturity

Solid and broadly based growth in strategic niche markets

- Spain, Austria, Luxembourg
- New niche markets added: Italy, Israel and Netherlands

Growing momentum in Asian markets

- Significantly stronger momentum, esp. in Singapore and Hong Kong, as the Asian hubs of global wholesale banks and platforms
- Local markets (Taiwan, China and others) addressed through local products or venture investors

Progress in ESG – the new market reality!

Sustainable and responsible investing with and in Bellevue

Corporate values

“Bellevue is committed to sustainable, responsible and values-driven business practices”



* UN GC = UN Global Compact, UN GPBHR = UN Guiding Principles for Business and Human Rights, ILO = International Labor Organisation



4

Outlook & Summary

André Rüegg, Group CEO

Outlook for 2021

Strong position enables a solid performance despite challenging environment

Business model shows high dependency on capital market

- Business model as a pure asset manager with a high dependency on the equity market, esp. the healthcare sector
- Still no alternative to equities due to structural financial market developments but high valuations and political developments call for cautious stance (setbacks)
- COVID-19: Reasonably accurate forecasts of future developments (new outbreaks, vaccination programs, etc.) and cost to the real economy not yet possible – and may not be possible for some time!

Solid starting position with clear strategic priorities for 2021

- Superb start in Q1 2021 created a financial cushion that will help to absorb any market setbacks
- Convincing product performance and clear positioning lead to strong new client pipeline
- Stepping up efforts to expand “Private Markets” unit and generate new ideas & innovation with diversification and differentiation potential
- More active use of StarCapital as a distribution hub is contributing to its revival

Strong financial footing

- Operating income flows are of high quality (margin) and reliability (high share of recurring revenue flows)
- Reduced organizational complexity will create further efficiency gains (2021/22)
- Straightforward and debt-free balance sheet
- Strong capital structure signals further value creation (esp. organic)

Outlook 2021

Long-term goals reiterated

1 *Assets under management (AuM)*

- Steady expansion of business base targeted, but depends on the market
- Organic new money growth in a range of 5-10% p.a.

2 *Profitable top-line growth*

- Asset-based revenues with higher margin quality and long-term growth of 7-10% p.a.
- Performance- and transaction-based revenues round out revenue mix

3 *Cost/income ratio (operating)*

- Short-term target range of 60-65% (adjusted, i.e. excl. non-recurring items)
- Medium-term target range of 55-60%

4 *Operating profit*

- Proportionally faster growth thanks to economies of scale in business model
- Stable and strong operating profits ensure steady dividend policy

5 *Return on equity*

- Continuation of shareholder-friendly dividend policy
- Attractive return on equity of >15%, thanks to strict capital management

6 *Performance quality*

- Very high percentage of our investment strategies beat their benchmark
- Very high percentage of our investment strategies are ranked in 1st and 2nd performance quartile

Summary

Bellevue now a pure asset manager with a clear positioning and promising potential

Successful transformation to a pure specialized asset manager

- Sale of Bank am Bellevue to Quintet Private Bank successfully closed in Q2 2020 despite the lockdown
- Bellevue Group has operated as a pure play asset manager with a clear positioning from H2 2020
- Reduced complexity of the overall business coupled with a substantial capital reserves gives management more flexibility and freedom

Strong operating and value creation performance

- Record financial results with AuM at all-time high, despite dramatic market turmoil
- Convincing investment performance attracts considerable sums of new money from new and existing clients, esp. in core “healthcare” segment
- Further improvement in profitability and release of no longer required regulatory capital ensures attractive value creation for shareholders


Business model demonstrates strong resilience and offers opportunities for further growth

- Simplified, robust and agile organization displays high level of resilience during “COVID-19 stress test”
- High level of investment expertise in healthcare helps to raise the Group’s international profile and reputation
- Stature as a “House of Ideas” continues to grow with ongoing corporate development and strong innovation



5

Questions & Answers







Appendix



*Additional details of
fiscal results 2020*

Consolidated financial statements

Consolidated income statement

CHF 1'000	1.1.-31.12.2020	1.1.-31.12.2019 restated	Change
Revenues from asset management services	108 819	102 156	+6 663
Income from financial investments	1 071	- 1 336	+2 407
Net other income	- 39	548	- 587
Operating income	109 851	101 368	+8 483 
Personal expenses	- 51 894	- 47 794	- 4 100
Other operating expenses	- 11 705	- 13 111	+1 406
Depreciation and amortization	- 4 777	- 4 247	- 530
Valuation adjustments and provisions	- 9 578	- 8 341	- 1 237
Operating expenses	- 77 954	- 73 493	- 4 461 
Taxes	- 8 875	- 8 415	- 460
Group net profit (continued operations)	23 022	19 460	+3 562 
Group net profit from discontinued operations (net of tax)	- 718	- 5 427	+ 4 709
Group net profit	22 304	14 033	+ 8 271 

Consolidated financial statements

Consolidated balance sheet as of December 31, 2020

CHF million

	Assets	Liabilities
	82.5	55.6
Cash and cash equivalents		
		4.3
Receivables	18.1	9.9
Financial investments	53.9	
Property and equipment	5.0	
Other assets	23.5	
Goodwill and intangible assets	52.6	
		165.8
		Shareholder's equity

- Asset side of balance sheet:
Current assets of CHF 156.4 mn,
non-current assets CHF 79.1 mn
- Liability side of balance sheet:
Current liabilities of CHF 45.1 mn,
non-current liabilities of
CHF 24.6 mn
- Debt-free balance sheet
- Equity of more than EUR 112 mn
after proposed dividend
- Strong capital base even after
proposed dividend payment

Consolidated financial statements

Alternative Performance Indicators

CHF 1'000	1.1.-31.12.2020	1.1.-31.12.2019 restated	Change
Operating income	109 851	101 368	+8 483
Personnel expenses	- 51 894	- 47 794	- 4 100
Other operating expenses	- 11 705	- 13 111	+1 406
Operating expenses	- 63 599	- 60 905	- 2 694
Operating profit	46 252	40 463	+5 789
Depreciation and amortization	- 4 777	- 4 247	- 530
Valuation adjustments	- 9 578	- 8 341	- 1 237
Group profit before tax (continuing operations)	31 897	27 875	4 022
Taxes	- 8 875	- 8 415	- 460
Group net profit (continuing operations)	23 022	19 460	+3 562
Group net profit from discontinued operations (net of tax)	- 718	- 5 427	+ 4 709
Group net profit	22 304	14 033	+ 8 271


Consolidated financial statements

Key figures

	2020	2019 restated	Change
Consolidate income statement/balance sheet			
Cost/Income ratio	57.9%	60.1%	-
Earnings per share (in CHF)	1.72	1.45	+18.6%
Equity per share (in CHF)	12.32	14.73	- 16.4%
Return on equity	21.7%	12.2%	-
Asset under management (in CHF million)			
Total managed assets	12 038	10 599	+13.6%
Net new money	377	422	-10.7%
Dividend			
Ordinary dividend per share (in CHF)	1.50	1.25	+20%
Special dividend per share (in CHF)	2.50	2.75	- 9%
Dividend yield (excl. special dividend)	4.9%	5.2%	-
Staff (FTEs)			
Number of staff (at cutoff date)	98.7	116.3	- 15.1%
Share price			
Share price of Bellevue Group registered shares (in CHF) as at 31.12.	30.80	23.90	+28.9%
Market capitalization (in CHF million)	415	322	+28.9%

Shareholder base

Structure of the shareholder base as of December 31, 2020





- Strong commitment of core shareholders
- Substantial increase in management/ employee shareholders (31.12.2019: 13.3%)
- Hansjörg Wyss a new core shareholder (9.7%) with a long-term horizon
- Base of institutional shareholders is steadily growing
- Very transparent shareholder base: >88% registered (1,971 shareholders)
- Shareholder-friendly dividend policy unchanged, strengthening sense of continuity

Bellevue Group shares (BBN SW)

Pleasing performance compared to relevant indexes and other asset managers

Total return in CHF (5 years)

Indexed to 100 (in %)



Market capitalization as of 31.12.2020

CHF 415 mn


Proposed dividend for 2020

CHF 1.50 (plus special dividend of CHF 2.50)

Dividend yield as of 31.12.2020

4.9% *

* Based on ordinary dividend of CHF 1.50 and share price on December 31, 2020



Business profile & strategy

Bellevue Group a "pure play" asset manager

Company profile and strategy



Business model = simple & clear

- Pure play asset manager
- Independent, entrepreneurial «multi-boutique»
- Active, unconstrained investment approach
- Unique spectrum of proven investment skills and performance
- Understandable, scalable business model



Philosophy = build value

- Prioritization of investment performance creates value for the client
- Participation in attractive product range with proven innovative capacity
- Share entrepreneurial success
- Ensure attractive value creation for all stakeholders



Financial profile = robust & low-risk

- Focus on sustained earnings power and growth
- Good balance between "specialty" and "diversification"
- Solid balance sheet, zero debt
- Strong base of core shareholders
- Shareholder-friendly dividend policy and attractive capital returns



Culture - "We eat our own cooking"

- Independent, efficient and entrepreneurial since 1993
- Strong financial commitment from all levels of the workforce
- Investment teams enjoy a considerable degree of autonomy (no CIO/investment committees)
- Quality and innovation are growth drivers
- Trust and entrepreneurial freedom («empowerment»)

Bellevue = «House of Ideas»

Client assets

CHF 12.0 bn

Top line

~CHF 110 mn p.a.

Number of employees (in FTE)

99

Shareholders' equity

CHF 112 mn *

Market cap

CHF 415 mn

Dividend yield


4.9% **

* After proposed payout

** Based on ordinary dividend of CHF 1.50 and share price on December 31, 2020


Attractive offering with clearly differentiated investment expertise

Good balance between “specialty” and “diversification” - for investors and shareholders!



International reach, locally anchored

Ongoing development of international business reach with a strong corporate culture



High workforce stability and quality

- Constantly growing talent pool
- Very low voluntary turnover rate
- Strong commitment from key individuals and talents at all units

On a growth track

- Ongoing expansion of international presence in Zurich, London and Frankfurt, growing talent pool
- International presence enhances distribution capacity

International market access

- Asset management licenses in 3 key markets: Switzerland, Germany/EU, UK
- Broad product range with clearly defined standards, easily transplanted across international borders

Business model and positioning enable more growth

Our growth drivers



Market performance



New money growth



Acquisitions

Growth drivers

Positioning and strengths

Basic thoughts & priorities

- Structural **growth themes** with solid fundamentals
- **Diversification** in quality, fixed income and multi-asset strategies
- **Market hedge** with uncorrelated strategies (alternative investments)
- Early identification / implementation of **attractive investment themes** («ideas»)
- **Further diversification:**
 - defensive strategies
 - absolute return
 - private market investments



- High level of **attractiveness and innovation** across the product range
- Competitive **performance and service quality** with long-term track records
- High level of investor trust thanks to **stability and continuity**
- Steadily growing **distribution and client network**
- Ability to penetrate **new markets**
- **Product innovation** / create new «ideas»
- Sharp **focus on quality**
- New **growth markets**



- Proven **experience and record of success** (Five transactions successfully completed)
- **Financial means** available (capital reserves)
- **Clear strategic priorities:**
 - strengthen AuM base
 - strengthen expertise
 - complementary add-ons
- Highly **selective** approach
- Clear focus on **smaller (team) deals** (complementary or reinforcing)
- Weigh up manageable **risks** and accept them



Selective expansion in private equity business

Focus on “Healthcare” and “Entrepreneurial Investments”

Private Equity Healthcare



- Target volume of USD 220 mn
- International, highly regarded investors on board
- Already ten attractive investments made / strong and promising pipeline
- Strong network partnership realized with **BASELAUNCH**
- Dr. Anja Harmeier (former Investment Director at Roche Venture Fund) joined the team

Private Equity DACH




- Ongoing inclusion of high-profile entrepreneurs and families in investor group
- Selective expansion of team to grow its capacity and talent pool
- Expansion & acceleration of deal flow – two participations concluded in 2020 / solid pipeline for 2021



- Investment fund subject to Swiss law (KmGK - Limited Partnership for Collective Investment/LP)
- Private-equity growth financing for SMEs
- Joint investments with the investor group
- Budgeted volume of CHF 100-120 mn


Progress towards ESG – the new market reality!

Major ESG investment milestones



Milestones in the Group's history

Headline events since the Group's establishment in 1993



Why turn to Bellevue Group?

Highlights Bellevue Group

“Pure” asset manager with a clear and simple business model

- Independent, efficient, entrepreneurial management style ever since it was established in 1993
- “Multi-boutique” with unique range of investment competencies and good balance between “specialty” and “diversification”
- Simple and straightforward business model with a sharp focus on quality and value creation

Attractive offering with clearly differentiated investment expertise


- Active and unconstrained investment approach
- Excellent long-term track record of investment strategies with above-average returns
- “House of Ideas”: Differentiated product offering and ability to create new ideas create value for the client

Robust and low-risk financial profile

- Sustainable earnings power (high level of recurring income) with attractive margins
- Solid balance sheet, zero debt
- Shareholder-friendly dividend policy and attractive capital returns
- 45.6% of outstanding shares held by core shareholders and employees

Significant potential for further growth

- Agile, highly scalable business model creates further opportunities for profitable growth
- Competitive performance and service quality combined with highly attractive, innovative product range enables sound expansion of business and income flows
- Experience, track record and financial leeway for inorganic growth already in place



*Update on important
investment products*

BB Biotech AG

Flagship product with convincing long-term performance track record

Strong NAV Outperformance

	2020 Share	2020 NAV	3 years	5 years	ITD
BB Biotech AG – CHF NBI	19.3% 15.8%	24.3% 15.8%	34.1% 31.1%	65.1% 22.1%	2848.7% 1353.3%
BB Biotech AG – USD NBI	30.9% 26.4%	35.9% 26.4%			

Two new, renowned members,
joined the Board of Directors

Further acquisitions in the portfolio
of BB Biotech AG

Moderna receives FDA emergency
use authorisation for COVID-19
vaccine

- With **Prof. Dr. Mads Krogsgaard Thomsen**, CSO of Novo Nordisk and **Dr. Susan Galbraith**, Head of Oncology of AstraZeneca, BB Biotech was able to attract two renowned new Board Members
- Due to the COVID-19 pandemic, M&A activity was severely impacted in H1 2020
- In the second half of 2020, with **Myokardia** (Bristol-Myers Squibb) and **Alexion** (AstraZeneca) **two important portfolio positions have been taken over**

- USD 47 bn market cap (an investment since Q1 2018)
- Pioneering mRNA based medicines – a broad clinical pipeline
- COVID-19 prophylactic vaccine candidate within only 42 days from sequence selection
- Initial dosing of healthy volunteers started in mid March 2020
- Phase III with 30'000 patients – primary efficacy analysis shows vaccine was 94.1% effective!
- **FDA – Emergency use authorisation as of December 18, 2020**

BB Healthcare Trust

Investing in the rapidly evolving healthcare paradigm

Strong outperformance of Share and NAV

Investing in the rapidly evolving healthcare paradigm

Inclusion in the FTSE 250

CareDx, Teladoc, Pacific Biosciences und Genmark with strong performance contributions

	2020 Share	2020 NAV	3 years	5 years	ITD
BB Healthcare Trust – GBP	29.1%	25.7%	66.2%	n.a.	98.2%
MSCI World Healthcare Net Return	10.3%	25.7%	42.1%	n.a.	62.3%
BB Healthcare Trust – USD	32.9%	29.4%			
MSCI World Healthcare Net Return	13.5%	29.4%			

- Re-invention of the entire healthcare system is necessary to meet the requirements of the 21st century population in a cost-effective manner. (e.g. strong increase in chronic diseases)
 - Portfolio is highly operationally geared to areas that would benefit from an inevitably changing healthcare paradigm (e.g. digitalization)
 - The management team currently overweight's the sub-sectors biotech, life science tools and diagnostic, the strongest underweight is in pharma
 - **BB Healthcare Trust was included in the FTSE 250 Index as of June 19, 2020**
-
- **CareDx**, provides products, drugs, testing services for transplant patients. Surprised with very strong Q3 2020 revenue numbers
 - **Teladoc**: telemedicine provider offering the perfect business model during the pandemic. Acquisition of Livongo creates the potential to evolve into a fully integrated “virtual-care-provider”
 - **Genmark**: specialises in “point-of-care” diagnostics for the diagnosis of pathogens in respiratory, gastrointestinal and blood infections (sepsis). Develops and distributes COVID-19 tests

BB Adamant Medtech & Services

Performance – Stability – Diversification

Fund outperforms broader healthcare markets despite a challenging environment

COVID-19 affects the fundamental factors of Medtech & Services only in the short-term

Positive outlook for 2021

Further innovations about to be introduced

	2020	3 years	5 years	ITD
BB Ada. Medtech & Services – USD-I	16.6%	66.8%	126.9%	320.6%
MSCI World HC Equip. & Supplies	23.9%	80.6%	147.2%	441.8%

- **Demand** is basically **non-cyclical**: health problems must be solved (e.g. heart issues, broken bones, glucose measurement and insulin injections)
- Certain elective procedures are deferred (e.g. hip and knee implants) as hospital capacity has been used for COVID-19 patients, and will result in pent-up demand

- We expect a **complete normalization** of elective medical procedures
- **Normalization of investor focus**: Fundamental data such as acceleration of organic sales growth, new products & services and clinical data are back in the spotlight
- Further **innovations** will be introduced in 2021 and we expect many new products and services to fuel sales growth, such as Dexcom G7, the Hugo robotic surgery system and MitraClip
- Managed Care will benefit from the elimination of the Health Insurance Fee (HIF)

BB Adamant Digital Health

Making the healthcare system more efficient with digital health

Stellar performance, even strongly outperforming Nasdaq 100

	2020	3 years	5 years	ITD
BB Adamant Digital Health – USD-I	68.4%	n.a.	n.a.	130.4%

COVID-19 crisis has accelerated the Digital Health Investment Case

- Digitization in healthcare is urgently needed and inevitable
- The coronavirus crisis has neutralized the natural reflex among the relevant stakeholders – patients, doctors, hospital administrators and payers – to reject such change...
- ...and even prompted some of them to actively support and invest in digital tools and solutions

Digital Health Investment Case becomes more predictable and even more attractive

- Telemedicine specialists and many other companies have made as much progress in 2020 as they would have **normally made in three or four years**
- The growing **acceptance of digital solutions** in the wake of the pandemic has pushed up the potential growth trajectory of the Digital Health Investment Case
- **The strong growth momentum and non-cyclical demand** suggest 2021 will be another pleasing year for Digital Health stocks

BB Adamant Biotech

Focused (40–50 holdings), global and mid cap-oriented approach

Strong absolute performance, slightly behind benchmark

At peak up to about 35% portfolio exposure to COVID-19

Favorable outlook for the biotech sector over the next 12 - 18 months

	2020	3 years	5 years	ITD
BB Adamant Biotech – USD-I NBI	23.9% 25.7%	36.3% 41.8%	28.2% 34.4%	428.8% 597.0%

BIONTECH
mRNA-vaccine with Pfizer

REGENERON
Antibody therapy
(Casirivimab & Imdevimab)

GILEAD
Antiviral medication
Remdesivir

moderna
mRNA-1273-vaccine

CUREVAC
Competitor of
Moderna/BioNtec

illumina
Diagnostics & sequencing

- New, promising therapeutic indications in immuno-oncology, liver diseases as well as rare diseases
- Political perception changes, added value of medicines becomes visible
- Biotech sector with sustained, strong sales and earnings growth
- Valuations, especially compared to pharma, are attractive

BB Adamant Healthcare Strategy / BB Adamant Sustainable Healthcare

40 holdings, four regions, off-benchmark, ESG integration vs. holistic ESG-approach

Both funds clearly outperform the MSCI World Healthcare Index

1 Underweight Pharma

2 Underweight US

3 Mid cap focus

Characteristics support attractiveness of both portfolios and underline our active approach

	2020	3 years	5 years	ITD
BB Ada. Healthcare Strategy – USD-I	27.9%	54.0%	n.a.	105.3%
MSCI World Healthcare Net Return	13.5%	43.4%	n.a.	74.7%
BB Ada. Sustainable Healthcare – USD-I	29.2%	n.a.	n.a.	41.8%
MSCI World Healthcare Net Return	13.5%	n.a.	n.a.	41.3%

- **Diversification pays off** again – clearly positive performance contributions from different sub-sectors, e.g. biotech and life science tools & services
- Healthcare in **emerging markets**, led by China, with compelling performance in 2020
- Negative performance contributions from underweight in large & mega caps more than offset thanks to exposure to **innovative mid caps**

EBITDA-Margin

~28%

Sales Growth

~14-17%

Active Share

~80%

BB Adamant Asia Pacific HC / BB Adamant Emerging Markets HC

Innovation and digitization generate sustainable growth

*Very competitive performance
of both investment strategies*

Digitization in Asia is progressing

Ongoing consolidation in Brazil

	2020	3 years	5 years	ITD
BB Ada. Asia Pacific HC – USD-I	45.0%	62.6%	n.a.	110.1%
MSCI Asia Pacific HC Net TR	33.0%	65.3%	n.a.	95.9%
BB Ada. Emerging Markets HC – USD-I	50.7%	50.2%	n.a.	80.8%
MSCI Emerging Markets HC Net TR	52.8%	25.3%	n.a.	55.6%

- With **JD Health** and **Ali Health**, all digital health subsidiaries of major Chinese tech companies are now listed at the stock exchange (incl. Ping An)
- "Facebook for Doctors" **M3** in Japan with first-ever drug co-development, focus on clinical development (IP and revenue share) and use of proprietary digital marketing after launch
- Indian hospital chain **Apollo Hospitals** successfully established its own telemedicine app

- Private healthcare sector enjoys increasing demand (lack of quality in public sector resources)
- **Hapvida** and **Notre Dame** have gained policyholders despite recession
- Both companies have also taken advantage of the "opportunity" of the poor economic situation and acquired numerous private providers

BB Entrepreneur Funds (I)

Solid balance sheets – the best medicine

Strong absolute returns

*Highly competitive vis-a-vis
benchmarks and peer groups*

*Phase I – COVID-19 shockwave
31.12.19 – 18.3.2020*

	2020	3 years	5 years	ITD
BB Entrepre. Europe Small – EUR-I <i>Benchmark*</i>	16.3% 11.7%	6.6% 20.9%	56.1% 53.4%	192.0% 189.0%
BB Entrepre. Europe – EUR-I <i>Stoxx Europe 600 Index</i>	1.9% -2.0%	4.8% 10.9%	23.9% 24.8%	214.2% 176.0%
BB Entrepre. Swiss Small & Mid – CHF-I <i>Benchmark**</i>	20.4% 8.1%	18.6% 16.7%	n.a. n.a.	49.1% 46.6%
BB Entrepre. Switzerland – CHF-A <i>SPI Index</i>	17.8% 3.8%	20.6% 24.0%	72.3% 46.6%	195.1% 115.3%

* MSCI Europe ex UK Small seit 18.05.15, MSCI Europe Small bis 15.05.15

** SPI Extra seit 30.11.17, SPI bis 30.11.17

- Markets collapse by one fifth (SPI) to one third (Europe Stoxx 600 and MSCI Europe Small ex UK) until mid of March
- **Advantageous Entrepreneur stocks** due to their lower debt quota and less pressure for dividend cuts
- **Technology and Healthcare** proved supportive throughout all portfolios, particularly both small and small&mid cap funds outperformed their benchmarks due to IT OW

zur Rose

+21.5%



Swissquote

-6.8%

arjo

+4.2%

- **Stock specific events** with positive contributions, e.g. Isra Vision (M&A), +23.0%
- **Increased focus on IT and Healthcare**, reduction of cyclicals (e.g. automotive suppliers) – purchase of CEWE, Huber+Suhner and increasing weight LEM, Logitech

BB Entrepreneur Funds (II)

Solid balance sheets – the best medicine

Phase II – Rebound in Q2 with stagnation during Summer / Breakout of second wave of infections

- **Recovery thanks to global support measures** – e.g. EU Recovery Fund and stimulus package of EUR 750 bn
- Partly **positive surprises regarding profitability of industrials** for Q2/2020, 70% of companies reported better than expected results for Q3
- **BB Entrepreneur Funds strongly recovered** and returned between 30% to 40%
- **Selective increase of «fallen angels»** in cyclicals (e.g. Moeller Maersk, Swatch, Arbonia), further addition of IT stocks (e.g. Software-One, VAT, Atea) and other positions (e.g. Husqvarna); partial profit taking in healthcare
- **On a special note:** participation in the IPO Knaus Tabbert (camping cars), Mediaset España (consolidation), Pierer Mobility (e-bikes, e-motorcycles); takeover of Sunrise by Liberty; reduction of Partners Group following its inclusion in the SMI Index

- **Positive COVID-19 vaccine studies** triggered market rally in Nov/Dec
- **US Presidential elections** and **Brexit agreement** supported geopolitical stability/visibility
- **Rotation** from quality/growth **into value/cyclicals**
- **Year-end rally of BB Entrepreneur Funds** between 16% and 21%

Outlook 2021

- Innovation, new consumer trends, technology and recovery of value stocks
- Rebound in GDP growth, the unwinding of pent-up demand in consumer spending and corporate investments and proactive fiscal policies being the pillar of recovery
- Digitalisation and ESG as structural growth themes

Phase III – Announcement of COVID-19 vaccines

Outlook 2021

BB Global Macro

Absolute return strategy with daily liquidity

High volatility but positive absolute performance

March drawdown was followed by a swift rebound

Base scenario for H1 2021 assumes stock markets will continue to advance

	2020	3 years	5 years	ITD
BB Global Macro – EUR-I LIBOR 3 Month	2.7% -0.4%	7.9% -1.2%	16.3% -1.8%	49.4% 0.9%

- **COVID-19 led to a brief but dramatic collapse** in economic activity, comparable to the financial crisis of 2008.
- Central banks resorted to extremely expansionary monetary policies, for example the **Fed expanded its balance sheet by USD 3.4 trillion**. Governments in many countries are providing additional economic support with fiscal spending packages.
- The magnitude of the drawdown is mainly attributed to short-term portfolio management decisions and not to our long-term stance that a portfolio consisting of 75% government bonds and 25% equities represents a very solid, neutral portfolio.

- Our **base scenario anticipates a slow economic recovery**. Vaccination campaigns will take time, but give markets good support to the downside
- In this scenario, we expect stock markets to march higher over the next 3-6 months (Dax +10%, S&P 500 +5%).
- At year end, the fund's **net exposure to equities was 30%, 25% to non-government bonds and 17% to long-term government bonds**.

Corporate Events & Contact

Corporate Events

March 23, 2021	Annual General Meeting 2021
July 29, 2021	Publication half-year report 2021

Investor Relations

Bellevue Group
Phone +41 44 267 67 00
Fax +41 44 267 67 01
ir@bellevue.ch

André Rüegg
CEO Bellevue Group
Phone +41 44 267 67 10
aru@bellevue.ch

Michael Hutter
CFO Bellevue Group
Phone +41 44 267 67 20
mhu@bellevue.ch

Media Relations

Jürg Stähelin
IRF Reputation AG
Phone +41 44 244 81 51
staehelin@irf-reputation.ch

Tanja Chicherio
Marketing Bellevue Group
Phone +41 44 267 67 07
tch@bellevue.ch